Finland to India: Natural Import Trade Route

The Finland to India Natural corridor is one of India's established pharmaceutical import routes from Finland, with 2 shipments documented worth a combined $4.3K USD. The route is dominated by Molnlycke Health Care AB , which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of Finland's natural export sector.

Across 1 active Finland suppliers, the average shipment value stands at $2.2K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with natural's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 32 days port-to-port. The route has recorded an annual growth rate of 34.4%, placing it at rank #11 among India's top natural import origins globally.

On the Indian buyer side, key Indian importers include MOLNLYCKE HEALTH CARE INDIA PRIVATE LIMITED . MOLNLYCKE HEALTH CARE INDIA PRIVATE LIMITED is the single largest Indian importer with 2 shipments valued at $4.3K USD.

India's natural imports from Finland are driven primarily by a handful of large-scale Finland manufacturers. Molnlycke Health Care AB with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from Finland supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — Molnlycke Health Care AB — together account for 100% of total trade value on this route. The average shipment value of $2.2K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

On the buying side, MOLNLYCKE HEALTH CARE INDIA PRIVATE LIMITED is the largest importer with 2 shipments worth $4.3K USD — representing 100% of all natural imports from Finland on this route.